Healthcare provider profile · identity verified

Shailesh Bhat, MD

Internal Medicine · WOODLAND HILLS, CA · NPI 1134288723

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	706	250
Amlodipine Besylate	Amlodipine Besylate	537	189
Losartan Potassium	Losartan Potassium	520	182
Rosuvastatin Calcium	Rosuvastatin Calcium	506	177
Lisinopril	Lisinopril	414	145
Levothyroxine Sodium	Levothyroxine Sodium	410	128
Atenolol	Atenolol	244	88
Metformin Hcl	Metformin Hcl	211	71
Naproxen	Naproxen	210	131
Famotidine	Famotidine	188	85
Gabapentin	Gabapentin	184	75
Terazosin Hcl	Terazosin Hcl	168	61
Glipizide	Glipizide	155	57
Tamsulosin Hcl	Tamsulosin Hcl	154	63
Alendronate Sodium	Alendronate Sodium	144	47
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	138	23
Metoprolol Tartrate	Metoprolol Tartrate	131	44
Albuterol Sulfate Hfa	Albuterol Sulfate	129	75
Finasteride	Finasteride	121	38
Hydrochlorothiazide	Hydrochlorothiazide	114	42
Potassium Chloride	Potassium Chloride	100	46
Trazodone Hcl	Trazodone Hcl	100	44
Metformin Hcl Er	Metformin Hcl	97	35
Pantoprazole Sodium	Pantoprazole Sodium	95	36
Omeprazole	Omeprazole	94	42
Meloxicam	Meloxicam	89	48
Simvastatin	Simvastatin	86	36
Triamcinolone Acetonide	Triamcinolone Acetonide	84	40
Sertraline Hcl	Sertraline Hcl	77	32
Hydralazine Hcl	Hydralazine Hcl	72	30
Prednisone	Prednisone	72	63
Pradaxa	Dabigatran Etexilate Mesylate	71	28
Fluocinonide	Fluocinonide	70	47
Furosemide	Furosemide	67	31
Carvedilol	Carvedilol	65	22
Lactulose	Lactulose	64	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	64	25
Allopurinol	Allopurinol	55	24
Ezetimibe	Ezetimibe	55	20
Ondansetron Odt	Ondansetron	55	25
Clopidogrel	Clopidogrel Bisulfate	54	20
Alprazolam	Alprazolam	51	15
Zolpidem Tartrate	Zolpidem Tartrate	49	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	48	48
Azithromycin	Azithromycin	45	43
Arexvy	Rsvpref3 Antigen/As01e/Pf	44	44
Duloxetine Hcl	Duloxetine Hcl	44	15
Fluticasone Propionate	Fluticasone Propionate	44	18
Hydrocortisone	Hydrocortisone	39	25
Ibuprofen	Ibuprofen	36	18
Oxycodone Hcl	Oxycodone Hcl	36	suppressed
Amoxicillin	Amoxicillin	35	31
Lorazepam	Lorazepam	35	suppressed
Spironolactone	Spironolactone	35	12
Pravastatin Sodium	Pravastatin Sodium	33	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	32	13
Ipratropium Bromide	Ipratropium Bromide	31	13
Tramadol Hcl	Tramadol Hcl	31	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	30	28
Fenofibrate	Fenofibrate	30	suppressed
Cromolyn Sodium	Cromolyn Sodium	29	18
Escitalopram Oxalate	Escitalopram Oxalate	29	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	28	25
Humulin N	Insulin Nph Human Isophane	28	13
Jardiance	Empagliflozin	28	13
Citalopram Hbr	Citalopram Hydrobromide	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	18
Estradiol	Estradiol	25	suppressed
Etodolac	Etodolac	25	14
Cephalexin	Cephalexin	23	23
Colchicine	Colchicine	23	suppressed
Meclizine Hcl	Meclizine Hcl	23	suppressed
Baclofen	Baclofen	21	suppressed
Ketoconazole	Ketoconazole	21	suppressed
Clonazepam	Clonazepam	19	suppressed
Metronidazole	Metronidazole	19	14
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	19	15
Alvesco	Ciclesonide	18	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Ozempic	Semaglutide	18	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	18	suppressed
Lovastatin	Lovastatin	17	suppressed
Trospium Chloride	Trospium Chloride	17	suppressed
Glipizide Er	Glipizide	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	15	11
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	15	14
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Erythromycin	Erythromycin Base	14	12
Ibandronate Sodium	Ibandronate Sodium	14	suppressed
Metoprolol Succinate	Metoprolol Succinate	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Temazepam	Temazepam	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Lidocaine	Lidocaine	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Nystatin	Nystatin	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Morphine Sulfate	Morphine Sulfate	11	suppressed
Paxlovid (Eua)	Nirmatrelvir/Ritonavir	11	11
Propranolol Hcl	Propranolol Hcl	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Terbinafine Hcl	Terbinafine Hcl	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error